Topic
15 research guides on slow-release t3 dosing & troubleshooting.
Tapering off Wilson's WT3 protocol after reaching the temperature target is a defined research-community process. Completion criteria, the 7.5 mcg taper schedule, what to monitor during weaning, and what happens if endogenous T3 production hasn't returned by protocol end.
Plateau on Wilson's WT3 protocol - reaching target temperature briefly then regressing, or never reaching target despite continued titration - is a discussed pattern in the bioenergetic research community. The T3 to T2 conversion bottleneck, reverse T3 re-accumulation, selenium and iron confounders, and the T3+T2 enhanced-protocol response.
When T3 doesn't produce the expected response, the bioenergetic research community has six framework explanations: dose too low, reverse T3 dominance, T3 to T2 conversion bottleneck, adrenal dysfunction, iron deficiency, autoimmune flare. The diagnostic framework and what research subjects do about each.
Why most labs report total T3 (bound + free) by default, what total T3 actually measures, thyroid-binding globulin considerations, estrogen effects on TBG, what to ask the lab for, and how to interpret total T3 when free T3 isn't available.
Slow release T3 absorption is meaningfully affected by food, calcium, iron, coffee, and soy. The research-community conservative recommendation: empty stomach, 60 minutes before food or 4 hours after. Mechanism, the specific interactions that matter, and when to make exceptions.
Morning headache on slow release T3 has a specific HPA-axis explanation - T3 sensitizing the cortisol awakening response in research subjects with adrenal dysfunction. The cortisol-crash pattern, dosing-timing adjustments, and the adrenal-cofactor framework the bioenergetic research community uses.
Missing a slow release T3 dose has a specific research-community decision tree: less than 4 hours late, take it; 4-12 hours late, judge by next-dose proximity; more than 12 hours late, skip and resume normal schedule. The pharmacokinetic rationale for never doubling up.
Insomnia on slow release T3 has two distinct patterns: classical T3 insomnia (overnight metabolic activation prevents sleep onset) and inverse T3 insomnia (T3 corrects cortisol-flatness so sleep IMPROVES). Mechanism, timing adjustments, and the diagnostic question that distinguishes the two patterns.
Heart palpitations on T3 have specific pharmacokinetic causes - the chronotropic effect of acute serum T3 surges. Mechanism, why SR-T3 reduces palpitations relative to immediate-release Cytomel, the magnesium-iron-cofactor angle, and when palpitations are a signal to stop the protocol entirely.
Anxiety on slow release T3 has specific mechanistic causes - beta-adrenergic sensitization from rapid serum peaks, HPA-axis activation, catecholamine substrate competition. Research-community framing of why the anxiety pattern occurs, why SR-T3's flatter curve reduces it relative to immediate-release Cytomel, and the dose-adjustment patterns research subjects commonly use.
The research-context starting dose for slow release T3 - the Wilson's WT3 lineage starts at 7.5 mcg every 12 hours; maintenance-protocol research subjects often start at 15-25 mcg once daily. Body-weight considerations, the titration tempo, and when to start lower.
Split dosing of slow release T3 - dividing the total daily dose into two or more administrations - is a research-community pattern with specific indications. The 12-hour Wilson's pattern, alternative split patterns, the pharmacokinetic argument, and when to switch from single-daily to split.
Morning vs evening slow release T3 dosing has a specific HPA-axis answer. Why most research subjects on single-daily SR-T3 dose in the morning to align with cortisol awakening, and the cases where evening or split AM+PM dosing is the research-community preference.
The complete 2026 research guide to slow release T3 dosing, titration, timing, and troubleshooting. Starting dose, titration schedule, morning vs evening timing, food and absorption, missed-dose protocol, the six explanations for T3 non-response, and the troubleshooting framework the bioenergetic research community has converged on for the SR-T3 protocol.
Free T3 lab reference range vs the symptom-resolution range research subjects target. The bioenergetic research framework's upper-third positioning, the comparison to symptom resolution, and what optimal Free T3 means in cyclic vs maintenance protocols.